CoChat
Sign Up
Cited by 281

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Progressive dopaminergic alterations and mitochondrial abnormalities in LRRK2 G2019S knock-in mice

Yue, M., Hinkle, K.M., Davies, P., Trushina, E., Fiesel, F.C., Christenson, T.A., Schroeder, A.S., Zhang, L., Bowles, E., Behrouz, B., Lincoln, S.J., Beevers, J.E., Milnerwood, A.J., Kurti, A., McLean, P.J., Fryer, J.D., Springer, W., Dickson, D.W., Farrer, M.J., Melrose, H.L.·2015·Neurobiology of Disease
DOI 10.1016/j.nbd.2015.02.031PMC PMC4526103
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.nbd.2015.02.031

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Multiple studies point to a role for LRRK2 at the presynaptic terminal where it plays a role in release of dopamine from striato-nigral neurons, and glutamate from corticostriatal neurons.

    “Multiple studies point to a role for LRRK2 at the presynaptic terminal where it plays a role in release of dopamine from striato-nigral neurons, and glutamate from corticostriatal neurons [5, 6, 11, 50, 86, 92, 95].”

    From Cellular and subcellular localization of Rab10 and phospho-T73 Rab10 in the mouse and human brain (2023) · cites this paper as [95]

    The Discussion (page unavailable) reports reduced striatal dopamine release in G2019S mice and proposes impaired vesicular exocytosis; it also reports increased glutamate release in cortical cultures. It does not establish glutamate release specifically from corticostriatal neurons, and it describes the dopamine projections as nigro-striatal rather than striato-nigral. (LLM, conf=0.86)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 111

  1. Angeles, 2011, Mutations in LRRK2 increase phosphorylation of peroxiredoxin 3 exacerbating oxidative stress-induced neuronal death, Hum. Mutat., 32, 1390, 10.1002/humu.21582 · DOI
  2. Arbuthnott, 1990, Dopamine release and metabolism in the rat striatum: an analysis by ‘in vivo’ brain microdialysis, Pharmacol. Ther., 48, 281, 10.1016/0163-7258(90)90050-C · DOI
  3. Bailey, 2013, LRRK2 phosphorylates novel tau epitopes and promotes tauopathy, Acta Neuropathol., 126, 809, 10.1007/s00401-013-1188-4 · DOI
  4. Bannon, 1983, Pharmacology of mesocortical dopamine neurons, Pharmacol. Rev., 35, 53, 10.1016/S0031-6997(25)06572-X · DOI
  5. Baptista, 2013, Loss of leucine-rich repeat kinase 2 (LRRK2) in rats leads to progressive abnormal phenotypes in peripheral organs, PLoS One, 8, e80705, 10.1371/journal.pone.0080705 · DOI
  6. Beccano-Kelly, 2014, Synaptic function is modulated by LRRK2 and glutamate release is increased in cortical neurons of G2019S LRRK2 knock-in mice, Front. Cell. Neurosci., 8, 301, 10.3389/fncel.2014.00301 · DOI · Paper page
  7. Beccano-Kelly, 2014, LRRK2 overexpression alters glutamatergic presynaptic plasticity, striatal dopamine tone, postsynaptic signal transduction, motor activity and memory, Hum. Mol. Genet., 24, 1336, 10.1093/hmg/ddu543 · DOI · Paper page
  8. Belluzzi, 2012, Presynaptic dysfunction in Parkinson's disease: a focus on LRRK2, Biochem. Soc. Trans., 40, 1111, 10.1042/BST20120124 · DOI
  9. Berger, 2010, Membrane localization of LRRK2 is associated with increased formation of the highly active LRRK2 dimer and changes in its phosphorylation, Biochemistry, 49, 5511, 10.1021/bi100157u · DOI
  10. Berwick, 2012, LRRK2 functions as a Wnt signaling scaffold, bridging cytosolic proteins and membrane-localized LRP6, Hum. Mol. Genet., 21, 4966, 10.1093/hmg/dds342 · DOI
  11. Cherra, 2013, Mutant LRRK2 elicits calcium imbalance and depletion of dendritic mitochondria in neurons, Am. J. Pathol., 182, 474, 10.1016/j.ajpath.2012.10.027 · DOI
  12. Cirnaru, 2014, LRRK2 kinase activity regulates synaptic vesicle trafficking and neurotransmitter release through modulation of LRRK2 macro-molecular complex, Front. Mol. Neurosci., 7, 49, 10.3389/fnmol.2014.00049 · DOI · Paper page
  13. Daberkow, 2013, Amphetamine paradoxically augments exocytotic dopamine release and phasic dopamine signals, J. Neurosci., 33, 452, 10.1523/JNEUROSCI.2136-12.2013 · DOI
  14. Darvesh, 2011, In vivo brain microdialysis: advances in neuropsychopharmacology and drug discovery, Expert Opin. Drug Discov., 6, 109, 10.1517/17460441.2011.547189 · DOI
  15. Davies, 2013, Comprehensive characterization and optimization of anti-LRRK2 (leucine-rich repeat kinase 2) monoclonal antibodies, Biochem. J., 453, 101, 10.1042/BJ20121742 · DOI
  16. Deng, 2008, Structure of the ROC domain from the Parkinson's disease-associated leucine-rich repeat kinase 2 reveals a dimeric GTPase, Proc. Natl. Acad. Sci. U. S. A., 105, 1499, 10.1073/pnas.0709098105 · DOI
  17. Di Fonzo, 2006, A common missense variant in the LRRK2 gene, Gly2385Arg, associated with Parkinson's disease risk in Taiwan, Neurogenetics, 7, 133, 10.1007/s10048-006-0041-5 · DOI
  18. Du, 2010, Early deficits in synaptic mitochondria in an Alzheimer's disease mouse model, Proc. Natl. Acad. Sci. U. S. A., 107, 18670, 10.1073/pnas.1006586107 · DOI · Paper page
  19. Dusonchet, 2011, A rat model of progressive nigral neurodegeneration induced by the Parkinson's disease-associated G2019S mutation in LRRK2, J. Neurosci., 31, 907, 10.1523/JNEUROSCI.5092-10.2011 · DOI
  20. Farrer, 2007, Lrrk2 G2385R is an ancestral risk factor for Parkinson's disease in Asia, Parkinsonism Relat. Disord., 13, 89, 10.1016/j.parkreldis.2006.12.001 · DOI
  21. Ferree, 2012, Regulation of physiologic actions of LRRK2: focus on autophagy, Neurodegener. Dis., 10, 238, 10.1159/000332599 · DOI
  22. Galter, 2006, LRRK2 expression linked to dopamine-innervated areas, Ann. Neurol., 59, 714, 10.1002/ana.20808 · DOI
  23. Galter, 2010, MitoPark mice mirror the slow progression of key symptoms and L-DOPA response in Parkinson's disease, Genes Brain Behav., 9, 173, 10.1111/j.1601-183X.2009.00542.x · DOI
  24. Giesert, 2013, Expression analysis of Lrrk1, Lrrk2 and Lrrk2 splice variants in mice, PLoS One, 8, e63778, 10.1371/journal.pone.0063778 · DOI
  25. Gomez-Suaga, 2014, LRRK2 delays degradative receptor trafficking by impeding late endosomal budding through decreasing Rab7 activity, Hum. Mol. Genet., 23, 6779, 10.1093/hmg/ddu395 · DOI · Paper page
  26. Greggio, 2008, The Parkinson disease-associated leucine-rich repeat kinase 2 (LRRK2) is a dimer that undergoes intramolecular autophosphorylation, J. Biol. Chem., 283, 16906, 10.1074/jbc.M708718200 · DOI
  27. Greggio, 2009, The Parkinson's disease kinase LRRK2 autophosphorylates its GTPase domain at multiple sites, Biochem. Biophys. Res. Commun., 389, 449, 10.1016/j.bbrc.2009.08.163 · DOI
  28. Healy, 2008, Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case–control study, Lancet Neurol., 7, 583, 10.1016/S1474-4422(08)70117-0 · DOI · Paper page
  29. Hernandez, 2012, Regulation of presynaptic neurotransmission by macroautophagy, Neuron, 74, 277, 10.1016/j.neuron.2012.02.020 · DOI
  30. Herzig, 2011, LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice, Hum. Mol. Genet., 20, 4209, 10.1093/hmg/ddr348 · DOI
  31. Herzig, 2012, High LRRK2 levels fail to induce or exacerbate neuronal alpha-synucleinopathy in mouse brain, PLoS One, 7, e36581, 10.1371/journal.pone.0036581 · DOI
  32. Higashi, 2007, Localization of Parkinson's disease-associated LRRK2 in normal and pathological human brain, Brain Res., 1155, 208, 10.1016/j.brainres.2007.04.034 · DOI
  33. Higashi, 2007, Expression and localization of Parkinson's disease-associated leucine-rich repeat kinase 2 in the mouse brain, J. Neurochem., 100, 368, 10.1111/j.1471-4159.2006.04246.x · DOI
  34. Hindle, 2013, Dopaminergic expression of the Parkinsonian gene LRRK2-G2019S leads to non-autonomous visual neurodegeneration, accelerated by increased neural demands for energy, Hum. Mol. Genet., 22, 2129, 10.1093/hmg/ddt061 · DOI
  35. Hinkle, 2012, LRRK2 knockout mice have an intact dopaminergic system but display alterations in exploratory and motor co-ordination behaviors, Mol. Neurodegener., 7, 25, 10.1186/1750-1326-7-25 · DOI
  36. Hinkle, 2012, LRRK2 knockout mice have an intact dopaminergic system but display alterations in exploratory and motor co-ordination behaviors, Mol. Neurodegener., 7, 25, 10.1186/1750-1326-7-25 · DOI
  37. Hulihan, 2008, LRRK2 Gly2019Ser penetrance in Arab-Berber patients from Tunisia: a case–control genetic study, Lancet Neurol., 7, 591, 10.1016/S1474-4422(08)70116-9 · DOI
  38. Ishihara, 2006, Clinical features of Parkinson disease patients with homozygous leucine-rich repeat kinase 2 G2019S mutations, Arch. Neurol., 63, 1250, 10.1001/archneur.63.9.1250 · DOI
  39. Ishihara, 2007, Screening for Lrrk2 G2019S and clinical comparison of Tunisian and North American Caucasian Parkinson's disease families, Mov. Disord., 22, 55, 10.1002/mds.21180 · DOI
  40. Kachergus, 2005, Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations, Am. J. Hum. Genet., 76, 672, 10.1086/429256 · DOI
  41. Kay, 2005, Escaping Parkinson's disease: a neurologically healthy octogenarian with the LRRK2 G2019S mutation, Mov. Disord., 20, 1077, 10.1002/mds.20618 · DOI
  42. Keating, 2008, Mitochondrial dysfunction, oxidative stress, regulation of exocytosis and their relevance to neurodegenerative diseases, J. Neurochem., 104, 298, 10.1111/j.1471-4159.2007.04997.x · DOI
  43. Kontgen, 1993, Simple screening procedure to detect gene targeting events in embryonic stem cells, Methods Enzymol., 225, 878, 10.1016/0076-6879(93)25055-7 · DOI
  44. Lee, 2010, Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease, Nat. Med., 16, 998, 10.1038/nm.2199 · DOI · Paper page
  45. Lee, 2015, Behavioral, neurochemical, and pathologic alterations in bacterial artificial chromosome transgenic G2019S leucine-rich repeated kinase 2 rats, Neurobiol. Aging, 36, 505, 10.1016/j.neurobiolaging.2014.07.011 · DOI
  46. Lewis, 2012, LRRK2 and human disease: a complicated question or a question of complexes?, Sci. Signal., 5, pe2, 10.1126/scisignal.2002680 · DOI
  47. Li, 2007, Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants, J. Neurochem., 103, 238, 10.1111/j.1471-4159.2007.04743.x · DOI
  48. Li, 2009, Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease, Nat. Neurosci., 12, 826, 10.1038/nn.2349 · DOI
  49. Li, 2010, Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S, J. Neurosci., 30, 1788, 10.1523/JNEUROSCI.5604-09.2010 · DOI
  50. Liao, 2014, Parkinson disease-associated mutation R1441H in LRRK2 prolongs the “active state” of its GTPase domain, Proc. Natl. Acad. Sci. U. S. A., 111, 4055, 10.1073/pnas.1323285111 · DOI
  51. Lin, 2009, Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein, Neuron, 64, 807, 10.1016/j.neuron.2009.11.006 · DOI
  52. Liu, 2014, LRRK2 R1441G mice are more liable to dopamine depletion and locomotor inactivity, Ann. Clin. Transl. Neurol., 1, 199, 10.1002/acn3.45 · DOI
  53. Longo, 2014, Genetic and pharmacological evidence that G2019S LRRK2 confers a hyperkinetic phenotype, resistant to motor decline associated with aging, Neurobiol. Dis., 71, 62, 10.1016/j.nbd.2014.07.013 · DOI
  54. MacLeod, 2006, The familial Parkinsonism gene LRRK2 regulates neurite process morphology, Neuron, 52, 587, 10.1016/j.neuron.2006.10.008 · DOI
  55. Mandemakers, 2012, LRRK2 expression is enriched in the striosomal compartment of mouse striatum, Neurobiol. Dis., 48, 582, 10.1016/j.nbd.2012.07.017 · DOI
  56. Manzoni, 2013, Inhibition of LRRK2 kinase activity stimulates macroautophagy, Biochim. Biophys. Acta, 1833, 2900, 10.1016/j.bbamcr.2013.07.020 · DOI
  57. Matta, 2012, LRRK2 controls an EndoA phosphorylation cycle in synaptic endocytosis, Neuron, 75, 1008, 10.1016/j.neuron.2012.08.022 · DOI · Paper page
  58. Melrose, 2006, Anatomical localization of leucine-rich repeat kinase 2 in mouse brain, Neuroscience, 139, 791, 10.1016/j.neuroscience.2006.01.017 · DOI
  59. Melrose, 2007, A comparative analysis of leucine-rich repeat kinase 2 (Lrrk2) expression in mouse brain and Lewy body disease, Neuroscience, 147, 1047, 10.1016/j.neuroscience.2007.05.027 · DOI
  60. Melrose, 2010, Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice, Neurobiol. Dis., 40, 503, 10.1016/j.nbd.2010.07.010 · DOI
  61. Migheli, 2013, LRRK2 affects vesicle trafficking, neurotransmitter extracellular level and membrane receptor localization, PLoS One, 8, e77198, 10.1371/journal.pone.0077198 · DOI
  62. Miklavc, 2014, Surfactant secretion in LRRK2 knock-out rats: changes in lamellar body morphology and rate of exocytosis, PLoS One, 9, e84926, 10.1371/journal.pone.0084926 · DOI
  63. Miyajima, 2015, The mouse/human cross-species heterodimer of leucine-rich repeat kinase 2: Possible significance in the transgenic model mouse of Parkinson's disease, Neurosci. Lett., 588, 142, 10.1016/j.neulet.2015.01.003 · DOI
  64. Mortiboys, 2010, Mitochondrial impairment in patients with Parkinson disease with the G2019S mutation in LRRK2, Neurology, 75, 2017, 10.1212/WNL.0b013e3181ff9685 · DOI
  65. Ness, 2013, Leucine-rich repeat kinase 2 (LRRK2)-deficient rats exhibit renal tubule injury and perturbations in metabolic and immunological homeostasis, PLoS One, 8, e66164, 10.1371/journal.pone.0066164 · DOI
  66. Ng, 2009, Parkin protects against LRRK2 G2019S mutant-induced dopaminergic neurodegeneration in Drosophila, J. Neurosci., 29, 11257, 10.1523/JNEUROSCI.2375-09.2009 · DOI
  67. Nichols, 2009, Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease, Biochem. J., 424, 47, 10.1042/BJ20091035 · DOI
  68. Niu, 2012, Leucine-rich repeat kinase 2 disturbs mitochondrial dynamics via Dynamin-like protein, J. Neurochem., 122, 650, 10.1111/j.1471-4159.2012.07809.x · DOI
  69. Ohta, 2013, Dominant-negative effects of LRRK2 heterodimers: a possible mechanism of neurodegeneration in Parkinson's disease caused by LRRK2 I2020T mutation, Biochem. Biophys. Res. Commun., 430, 560, 10.1016/j.bbrc.2012.11.113 · DOI
  70. Orenstein, 2013, Interplay of LRRK2 with chaperone-mediated autophagy, Nat. Neurosci., 16, 394, 10.1038/nn.3350 · DOI · Paper page
  71. Ozelius, 2006, LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews, N. Engl. J. Med., 354, 424, 10.1056/NEJMc055509 · DOI
  72. Papkovskaia, 2012, G2019S leucine-rich repeat kinase 2 causes uncoupling protein-mediated mitochondrial depolarization, Hum. Mol. Genet., 21, 4201, 10.1093/hmg/dds244 · DOI
  73. Parisiadou, 2014, LRRK2 regulates synaptogenesis and dopamine receptor activation through modulation of PKA activity, Nat. Neurosci., 17, 367, 10.1038/nn.3636 · DOI
  74. Piccoli, 2011, LRRK2 controls synaptic vesicle storage and mobilization within the recycling pool, J. Neurosci., 31, 2225, 10.1523/JNEUROSCI.3730-10.2011 · DOI
  75. Ross, 2008, Analysis of Lrrk2 R1628P as a risk factor for Parkinson's disease, Ann. Neurol., 64, 88, 10.1002/ana.21405 · DOI
  76. Ross, 2011, Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case-control study, Lancet Neurol., 10, 898, 10.1016/S1474-4422(11)70175-2 · DOI
  77. Saez-Atienzar, 2014, The LRRK2 inhibitor GSK2578215A induces protective autophagy in SH-SY5Y cells: involvement of Drp-1-mediated mitochondrial fission and mitochondrial-derived ROS signaling, Cell Death Dis., 5, e1368, 10.1038/cddis.2014.320 · DOI
  78. Saha, 2009, LRRK2 modulates vulnerability to mitochondrial dysfunction in Caenorhabditis elegans, J. Neurosci., 29, 9210, 10.1523/JNEUROSCI.2281-09.2009 · DOI
  79. Sanders, 2014, LRRK2 mutations cause mitochondrial DNA damage in iPSC-derived neural cells from Parkinson's disease patients: reversal by gene correction, Neurobiol. Dis., 62, 381, 10.1016/j.nbd.2013.10.013 · DOI
  80. Schapansky, 2014, Membrane recruitment of endogenous LRRK2 precedes its potent regulation of autophagy, Hum. Mol. Genet., 23, 4201, 10.1093/hmg/ddu138 · DOI · Paper page
  81. Sen, 2009, Dependence of leucine-rich repeat kinase 2 (LRRK2) kinase activity on dimerization, J. Biol. Chem., 284, 36346, 10.1074/jbc.M109.025437 · DOI
  82. Sharp, 1986, An in vivo study of dopamine release and metabolism in rat brain regions using intracerebral dialysis, J. Neurochem., 47, 113, 10.1111/j.1471-4159.1986.tb02838.x · DOI
  83. Skibinski, 2014, Mutant LRRK2 toxicity in neurons depends on LRRK2 levels and synuclein but not kinase activity or inclusion bodies, J. Neurosci., 34, 418, 10.1523/JNEUROSCI.2712-13.2014 · DOI
  84. Sossi, 2002, Increase in dopamine turnover occurs early in Parkinson's disease: evidence from a new modeling approach to PET 18F-fluorodopa data, J. Cereb. Blood Flow Metab., 22, 232, 10.1097/00004647-200202000-00011 · DOI
  85. Sossi, 2004, Changes of dopamine turnover in the progression of Parkinson's disease as measured by positron emission tomography: their relation to disease-compensatory mechanisms, J. Cereb. Blood Flow Metab., 24, 869, 10.1097/01.WCB.0000126563.85360.75 · DOI
  86. Sossi, 2010, Dopamine turnover increases in asymptomatic LRRK2 mutations carriers, Mov. Disord., 25, 2717, 10.1002/mds.23356 · DOI
  87. Stafa, 2014, Functional interaction of Parkinson's disease-associated LRRK2 with members of the dynamin GTPase superfamily, Hum. Mol. Genet., 23, 2055, 10.1093/hmg/ddt600 · DOI
  88. Sterky, 2012, Altered dopamine metabolism and increased vulnerability to MPTP in mice with partial deficiency of mitochondrial complex I in dopamine neurons, Hum. Mol. Genet., 21, 1078, 10.1093/hmg/ddr537 · DOI
  89. Su, 2013, Inhibition of excessive mitochondrial fission reduced aberrant autophagy and neuronal damage caused by LRRK2 G2019S mutation, Hum. Mol. Genet., 22, 4545, 10.1093/hmg/ddt301 · DOI
  90. Sulzer, 2005, Mechanisms of neurotransmitter release by amphetamines: a review, Prog. Neurobiol., 75, 406, 10.1016/j.pneurobio.2005.04.003 · DOI
  91. Tan, 2006, Identification of a common genetic risk variant (LRRK2 Gly2385Arg) in Parkinson's disease, Ann. Acad. Med. Singapore, 35, 840, 10.47102/annals-acadmedsg.V35N11p840 · DOI
  92. Taymans, 2006, Distribution of PINK1 and LRRK2 in rat and mouse brain, J. Neurochem., 98, 951, 10.1111/j.1471-4159.2006.03919.x · DOI
  93. Tong, 2009, R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice, Proc. Natl. Acad. Sci. U. S. A., 106, 14622, 10.1073/pnas.0906334106 · DOI
  94. Tong, 2010, Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of alpha-synuclein, and apoptotic cell death in aged mice, Proc. Natl. Acad. Sci. U. S. A., 107, 9879, 10.1073/pnas.1004676107 · DOI
  95. Tong, 2012, Loss of leucine-rich repeat kinase 2 causes age-dependent bi-phasic alterations of the autophagy pathway, Mol. Neurodegener., 7, 2, 10.1186/1750-1326-7-2 · DOI
  96. Trushina, 2012, Defects in mitochondrial dynamics and metabolomic signatures of evolving energetic stress in mouse models of familial Alzheimer's disease, PLoS One, 7, e32737, 10.1371/journal.pone.0032737 · DOI
  97. Tsika, 2014, Conditional expression of Parkinson's disease-related R1441C LRRK2 in midbrain dopaminergic neurons of mice causes nuclear abnormalities without neurodegeneration, Neurobiol. Dis., 71, 345, 10.1016/j.nbd.2014.08.027 · DOI
  98. Walker, 2014, Behavioral deficits and striatal DA signaling in LRRK2 p.G2019S transgenic rats: a multimodal investigation including PET neuroimaging, J. Parkinsons Dis., 4, 483, 10.3233/JPD-140344 · DOI
  99. Wang, 2011, DLP1-dependent mitochondrial fragmentation mediates 1-methyl-4-phenylpyridinium toxicity in neurons: implications for Parkinson's disease, Aging Cell, 10, 807, 10.1111/j.1474-9726.2011.00721.x · DOI
  100. Wang, 2012, LRRK2 regulates mitochondrial dynamics and function through direct interaction with DLP1, Hum. Mol. Genet., 21, 1931, 10.1093/hmg/dds003 · DOI
  101. Webber, 2011, Autophosphorylation in the leucine-rich repeat kinase 2 (LRRK2) GTPase domain modifies kinase and GTP-binding activities, J. Mol. Biol., 412, 94, 10.1016/j.jmb.2011.07.033 · DOI
  102. West, 2014, Differential LRRK2 expression in the cortex, striatum, and substantia nigra in transgenic and nontransgenic rodents, J. Comp. Neurol., 522, 2465, 10.1002/cne.23583 · DOI · Paper page
  103. Westerink, 1985, Sequence and significance of dopamine metabolism in the rat brain, Neurochem. Int., 7, 221, 10.1016/0197-0186(85)90108-1 · DOI
  104. Westerlund, 2008, Developmental regulation of leucine-rich repeat kinase 1 and 2 expression in the brain and other rodent and human organs: implications for Parkinson's disease, Neuroscience, 152, 429, 10.1016/j.neuroscience.2007.10.062 · DOI
  105. Westerlund, 2008, Lrrk2 and alpha-synuclein are co-regulated in rodent striatum, Mol. Cell. Neurosci., 39, 586, 10.1016/j.mcn.2008.08.001 · DOI
  106. Yakhine-Diop, 2014, G2019S LRRK2 mutant fibroblasts from Parkinson's disease patients show increased sensitivity to neurotoxin 1-methyl-4-phenylpyridinium dependent of autophagy, Toxicology, 324, 1, 10.1016/j.tox.2014.07.001 · DOI
  107. Zetterstrom, 1986, Effect of dopamine D-1 and D-2 receptor selective drugs on dopamine release and metabolism in rat striatum in vivo, Naunyn Schmiedeberg's Arch. Pharmacol., 334, 117, 10.1007/BF00505810 · DOI
  108. Zetterstrom, 1988, In vivo measurement of extracellular dopamine and DOPAC in rat striatum after various dopamine-releasing drugs; implications for the origin of extracellular DOPAC, Eur. J. Pharmacol., 148, 327, 10.1016/0014-2999(88)90110-0 · DOI
  109. Zhou, 2011, Temporal expression of mutant LRRK2 in adult rats impairs dopamine reuptake, Int. J. Biol. Sci., 7, 753, 10.7150/ijbs.7.753 · DOI
  110. Zigmond, 2002, Increased dopamine turnover after partial loss of dopaminergic neurons: compensation or toxicity?, Parkinsonism Relat. Disord., 8, 389, 10.1016/S1353-8020(02)00019-6 · DOI
  111. Zimprich, 2004, Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology, Neuron, 44, 601, 10.1016/j.neuron.2004.11.005 · DOI

Cited by

Sorted by citations

Metadata

Authors
Yue, M., Hinkle, K. M., Davies, P., Trushina, E., Fiesel, F. C., Christenson, T. A., Schroeder, A. S., Zhang, L., Bowles, E., Behrouz, B., Lincoln, S. J., Beevers, J. E., Milnerwood, A. J., Kurti, A., McLean, P. J., Fryer, J. D., Springer, W., Dickson, D. W., Farrer, M. J., & Melrose, H. L.
Venue
Neurobiology of Disease
Publisher
Elsevier BV
Published
2015-06
Volume
78
Pages
172-195
ISSN
0969-9961
DOI
10.1016/j.nbd.2015.02.031
PMC
PMC4526103
Cited by
281
References
3
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Funders
  • Mayo Clinic
  • NIH (NS065860, NS40256, NS072187, ES020715, NS073740)
  • Alzheimer's Association
  • Michael J. Fox Foundation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review